AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00847821 — intervention group
Intervention type: DRUG
Intervention: Bazedoxifene 10 mg/CE 0.45 mg
Description: No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
Study NCT00847821 — intervention group
Intervention type: DRUG
Intervention: Bazedoxifene 20 mg/CE 0.45 mg
Description: No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
Study NCT00847821 — intervention group
Intervention type: DRUG
Intervention: Bazedoxifene 40 mg/CE 0.45 mg
Description: No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
Study NCT00847821 — intervention group
Intervention type: DRUG
Intervention: Raloxifene 60 mg
Description: No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as raloxifene tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
Study NCT00847821 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
Study NCT03743896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Glucosamine Cream
Study NCT01334944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen
Description: 400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
Study NCT02387437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SI recruitment
Description: SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
Study NCT02387437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP recruitment
Description: Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
Study NCT02387437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCV recruitment
Description: PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
Study NCT00803166 — intervention group
Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Cream-Reference Product
Description: Small amount applied and evaluated over the course of three days
Study NCT00803166 — intervention group
Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Cream-Test product 1
Description: Small amount applied and evaluated over the course of three days
Study NCT00803166 — intervention group
Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Cream-Test Product 2
Description: Small amount applied and evaluated over the course of three days
Study NCT04068363 — intervention group
Intervention type: OTHER
Intervention: non interventional
Description: non interventional study
Study NCT03260127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized executive function training plus CPT (CEFT-CPT)
Description: Participants randomized to the CEFT-CPT arm will receive 6 weeks of computerized executive function training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
Study NCT03260127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Word game training plus CPT (WT-CPT)
Description: Participants randomized to the WT-CPT arm will receive 6 weeks of computerized word game training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
Study NCT02803060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formaulation number- SR15-62 -Z15-038).
Study NCT03325205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal Transcranial direct current stimulation (tDCS) is a non- invasive brain stimulation technique. Low intensity current (1-2 mA) is induced to increase excitability, stimulate plasticity and enhance cognitive functions.
Study NCT03325205 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The electrodes are placed over the same areas as in the anodal tDCS condition. Participants will receive sham tDCS instead of anodal tDCS
Study NCT04380298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30ml of local infiltration solution containing 60mg ropivacaine
Study NCT04380298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30ml of local infiltration solution containing 6mg ketorolac
Study NCT04380298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 30ml of local infiltration solution containing 6mg ketorolac
Study NCT04380298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 30ml of local infiltration solution containing 0.1mg epinephrine
Study NCT04380298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 30ml of local infiltration solution containing 0.1mg epinephrine
Study NCT03394456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes program
Description: Comprehensive diabetes program (weekly to bimonthly CHW mHealth contact (phone, text) for 12-months and monthly diabetes group visits for 6-months)
Study NCT03394456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telehealth training and support for Community Health Workers
Description: weekly 1-hour diabetes training and patient support for CHWs via telehealth i.e., ZOOM technology for the study duration
Study NCT04297787 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thrombolysis in combination with endhole aspiration
Description: The treatment protocol the study team will be following is as follows. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
Study NCT04651114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision-making tool
Description: Women will be directed to a secure website to download a copy of the decision making tool and worksheets (they can download as many copies as they wish to). The women will use the tool and worksheets at their own pace for the pilot study period.~The decision making tool is a 23-page tool and set of 9 downloadable worksheets. The tool covers topics relevant to women with disabilities in considering or planning a pregnancy: 1) Overview of Pregnancy: 2) Knowing what is important; 3) Partners, family and important relationships; 4) Physical function and independence; 5) Health and wellbeing; 6) Caring for an infant; 7) Financial resources \& insurance; 8) How to find reliable information and resources; 9) Connecting with other women with physical disabilities; 10) Dealing with reactions of others, stigma and bias, pressure; and 11) Reaching a decision.
Study NCT01713699 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar puncture
Study NCT02674932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identifying and Using Signature Strengths
Description: The purpose of the intervention is to identify and focus on one's morally valued strengths and utilize them (i.e. incorporate them into coping skills) to overcome challenges. The study team member and patient will discuss each top strength and ways to use them as coping skills. The patient will identify 2-4 coping mechanisms per strength, and will write his/her strengths and self-identified coping skills on index cards.
Study NCT02674932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Identifying and Writing Down Coping Skills
Description: The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify at least six coping skills and write them down on index cards.
Study NCT02674932 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify coping skills that could be helpful (but will not write them down).
Study NCT04169919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Povidone-Iodine 5% eye wash
Study NCT04169919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Flush
Description: Normal Saline eye wash
Study NCT02317224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-Hole subxiphorid and subcostal approach
Description: 3-Hole subxiphorid and subcostal approach anterior mediastinum tumor resection
Study NCT02317224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans sternal approach
Description: Trans sternal approach anterior mediastinum tumor resection
Study NCT02317224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS approach
Description: Video-assisted thoracoscope anterior mediastinum tumor resection
Study NCT01413672 — intervention group
Intervention type: DEVICE
Intervention: Use of CASTLE barrier
Description: Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
Study NCT00981474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blood pressure maintenance based on cerebral blood flow autoregulation measurement
Description: Blood pressure lowered or raised
Study NCT00981474 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Institutional standard of care.
Study NCT01849120 — intervention group
Intervention type: DEVICE
Intervention: EQUANOX Advance 8004CB sensor
Description: The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
Study NCT00819403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
Study NCT00819403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe/simvastatin
Description: Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
Study NCT03313219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentuximab Injection
Description: Gentuximab Injection (Recombinant anti-VEGFR2 human-mouse chimeric monoclonal antibody injection)
Study NCT00764192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample before and after a single HD
Study NCT00764192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD) before and after a single HD
Description: measuring of the flow-mediated dilation using high-resolution ultrasound
Study NCT02606955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIA DW
Description: All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
Study NCT01190215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: One Intramuscular injection
Study NCT01190215 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)
Description: Two Intramuscular injections
Study NCT04199533 — intervention group
Intervention type: BEHAVIORAL
Intervention: RUBI
Description: Parent-mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
Study NCT04199533 — intervention group
Intervention type: BEHAVIORAL
Intervention: RUBIES
Description: School-staff mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
Study NCT02185885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Increased bloodpressure during CPB.
Study NCT02446925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surefire® Infusion System
Description: Utilization of Surefire® Infusion System for Y-90 glass microsphere embolization
Study NCT02446925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard End-hole catheter
Description: Utilization of Standard End-hole catheter for Y-90 glass microsphere embolization
Study NCT02482272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine 100mg/day orally
Study NCT02482272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: Adefovir 10mg/day orally
Study NCT02482272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Adefovir 10mg/day orally
Study NCT02482272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 1mg/day orally
Study NCT05800808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity Intervals
Description: 8x4 min cycling bouts at 85% of VO2peak
Study NCT05800808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Exercise
Description: 81 minutes of cycling at 50% VO2peak
Study NCT01671839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous tissue release with the Cabochon System
Description: Device: Subcutaneous tissue release
Study NCT01279330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-signed Letter
Description: Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
Study NCT01279330 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: No intervention (Patients receive by mail the materials needed for stool samples).
Study NCT02670252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT02670252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT02670252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT02670252 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation (TBI)
Description: Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
Study NCT05039762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomosis
Description: Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. When the right hemicolon is sufficiently mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated, a horizontal incision in the upper right quadrant is made. Through this incision the right hemicolon is extracted, the small bowel and the transverse colon are divided using staplers. The side-to-side ileocolic anastomosis is then handsewn.
Study NCT03368885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of existing platforms VHSND
Description: Convergence- Strengthen Village Health Sanitation and Nutrition Day for creating awareness on diet diversity for maternal nutrition and complementary feeding
Study NCT03368885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategic use of data
Description: Strategic use of data-Data analysis for concurrent monitoring,planning and decision making to improve the performance of CMCs
Study NCT03033316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT05039762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Description: Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. The right hemicolon is mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated. The small bowel and the transverse colon are then divided using laparoscopic staplers. The side-to-side ileocolic anastomosis is formed by creating a small opening in the small bowel and the transverse colon, through which the laparoscopic stapler is used to join the bowel ends. The remaining opening is sutured laparoscopically. The specimen is retrieved through a Pfannenstiel incision.
Study NCT02163655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUROSEMIDE
Description: Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
Study NCT02163655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
Study NCT01619657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% Hypertonic Saline (HS), 4mL
Description: Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
Study NCT01619657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Isotonic Saline (IS), 4mL
Description: Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
Study NCT01449240 — intervention group
Intervention type: OTHER
Intervention: No treatment
Study NCT02914184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRV PCV-free liquid vaccine
Description: Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
Study NCT02914184 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
Study NCT00612222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.
Study NCT00612222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC MART-1 Vaccine
Description: ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.
Study NCT00612222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
Study NCT00612222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
Study NCT00612222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days